Research Article Details
| Article ID: | A25368 |
| PMID: | 21912741 |
| Source: | J Nutr Metab |
| Title: | Putative factors that may modulate the effect of exercise on liver fat: insights from animal studies. |
| Abstract: | An increase in intrahepatic triglyceride (IHTG) content is the hallmark of nonalcoholic fatty liver disease (NAFLD) and is strongly associated with insulin resistance and dyslipidemia. Although regular aerobic exercise improves metabolic function, its role in regulating fat accumulation in the liver is incompletely understood, and human data are scarce. Results from exercise training studies in animals highlight a number of potential factors that could possibly mediate the effect of exercise on liver fat, but none of them has been formally tested in man. The effect of exercise on IHTG content strongly depends on the background diet, so that exercise is more effective in reducing IHTG under conditions that favor liver fat accretion (e.g., when animals are fed high-fat diets). Concurrent loss of body weight or visceral fat does not appear to mediate the effect of exercise on IHTG, whereas sex (males versus females), prandial status (fasted versus fed), and duration of training, as well as the time elapsed from the last bout of exercise could all be affecting the observed exercise-induced changes in IHTG content. The potential importance of these factors remains obscure, thus providing a wide array of opportunities for future research on the effects of exercise (and diet) on liver fat accumulation. |
| DOI: | 10.1155/2012/827417 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |